ITCI - Intra-Cellular Brightens MDD Outlook With Caplyta Success
2024-06-19 02:08:12 ET
Summary
- Caplyta (lumateperone) shows significant promise as an adjunctive treatment for Major Depressive Disorder.
- Caplyta's unique pharmacological profile targeting serotonin, dopamine, and glutamate pathways sets it apart in the saturated MDD market.
- Intra-Cellular's financial stability is supported by strong sales growth and sufficient cash reserves to sustain operations until 2027.
- I recommend buying ITCI stock as a high-risk, high-return component of a barbell investment strategy.
Intra-Cellular's Caplyta Shows Promise in Major Depressive Disorder
In a November article , I wrote about Intra-Cellular's ( ITCI ) Caplyta (lumateperone), a drug approved to treat schizophrenia and bipolar depression. The article was particularly focused on the drug's potential for Major Depressive Disorder ((MDD)). I had high expectations for important Phase 3 readouts....
Intra-Cellular Brightens MDD Outlook With Caplyta Success